

News Releases

All Years

Search

Go

[Advanced Search](#)

NOV 13, 2020

Inhibrx Reports Financial Results for the Third Quarter 2020 and Announces Amended Loan Agreement with Oxford

NOV 11, 2020

Inhibrx Announces Positive Interim Results from the Phase 1 Trial of INBRX-109 in Chondrosarcoma Patients

NOV 5, 2020

Inhibrx Announces Participation in Upcoming Investor and Scientific Conferences

AUG 21, 2020

Inhibrx Announces Closing of Initial Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

AUG 18, 2020

Inhibrx Announces Pricing of Initial Public Offering of Common Stock

JAN 8, 2020

Inhibrx Announces Dosing of First Patient in Phase 1 Dose-Escalation Study of INBRX-106, a Novel Hexavalent Agonist of OX40

SEP 4, 2019

Inhibrx Announces Enrollment of First Patient in Phase 1 Study of INBRX-101, a Modified Recombinant Human AAT-Fc Fusion Protein

SEP 3, 2019

Inhibrx Reports Phase 1 Dose Escalation Results of INBRX-109, a Multivalent Agonist of Death Receptor 5

MAY 30, 2019

Inhibrx Announces Option Agreement for Development and Commercialization of INBRX-101 (AAT-Fc) Outside of the United States and Canada with Chiesi Group

MAY 21, 2019

Inhibrx Announces \$40M Investment from Viking Global Investors

Show 10  per page

«	1	2	3	4	5	6	7	»
-------------------	-------------------	-------------------	-------------------	-------------------	-------------------	---	-------------------	-------------------



<https://inhibrx.investorroom.com/news-releases?l=10&o=50>